Bristol-Myers Squibb CompanyNYSE: BMY
Health Care · Pharmaceuticals
$58.19
-3.97%
Vol: 12.7M
Research Digest
Friday, May 1, 2026
Bristol Myers Squibb beats Q1 earnings expectations with 5.21% stock surge; strong growth portfolio and Eliquis rebound drive optimism
Bristol Myers Squibb reported Q1 2026 adjusted EPS of $1.58 (beat consensus of $1.42) with revenue up 3% YoY to $11.5B, led by growth portfolio at 12% growth ($6.2B). Eliquis revenue surged 13% to $4.1B despite U.S. price reductions, and Breyanzi grew 53% reflecting strong demand. Company maintained 2026 guidance of $46-47.5B revenue and $6.05-6.35 EPS. Stock soared 5.21% and outperformed healthcare sector by 2.86%. Legacy portfolio declined 6% to $5.3B, presenting near-term headwinds.
Previous Market Intelligence
13 daysApr 30Bristol Myers Squibb Q1 earnings expected to show 20% EPS decline and 2.5% revenue dropNegative▶
Bristol Myers Squibb faces headwinds heading into Q1 earnings with analysts expecting 20% EPS decline and 2.5% revenue decline YoY due to legacy drug declines. Recent collaborations with Mark Cuban's Cost Plus Drug Company for Eliquis pricing transparency and Foundation Medicine for oncology diagnostics show strategic positioning. Current stock price $57.61 with 4.3% dividend yield and 16.84 P/E. Company navigating transition toward growth portfolio while managing legacy product erosion. Mixed analyst sentiment reflects uncertainty around earnings execution and pipeline growth catalysts.
Apr 29Bristol Myers Squibb Q1 earnings April 30 with EPS decline 20% YoY to ~$1.57, revenue down 2.5% YoYMixed▶
Bristol Myers Squibb reports Q1 2026 earnings April 30 with analyst expectations for 20% EPS decline YoY and 2.5% revenue decline to ~$11.3B. Company's 2026 revenue guidance $46B-$47.5B (down from $48.2B in 2025) reflects concern over Eliquis patent expiration approaching. Stock up 20% over past year but down 2.6% over past month. BMY partnered with Mark Cuban's Cost Plus Drugs to offer Eliquis on CostPlusDrugs.com. Analyst consensus "Moderate Buy" expects adjusted EPS of $6.28 (+2.1% YoY) for full year 2026.
Apr 16Bristol Myers Squibb Q1 2026 earnings due April 30; FDA rejected Replimune/Opdivo combo skin cancer application due to study design concernsMixed▶
Bristol Myers Squibb will report Q1 2026 earnings on April 30, 2026. The company faces a regulatory setback with the FDA refusing to file Replimune application for its experimental skin cancer drug in combination with BMY Opdivo for advanced melanoma due to study design concerns. The company licensed five inflammatory and immune disorder drugs to newly created startup Beeline Medicines for $300 million, including development of a potential daily lupus pill. BofA analyst Jason Gerberry maintains Buy rating at $67 PT. With 38 analyst coverage showing 10 Buy, 18 Hold, and 1 Sell, the median price target is $64.00.
Apr 14Bristol Myers announces positive Camzyos adolescent trial and Microsoft AI collaboration for lung cancerPositive▶
Positive Phase 3 SCOUT-HCM for Camzyos in adolescents. Microsoft AI collaboration for lung cancer detection. Positive mezigdomide myeloma data. Q1 earnings April 30.
Apr 13Positive Camzyos adolescent data; Sotyktu FDA approval for psoriatic arthritis; Q1 earnings April 30Positive▶
Bristol Myers Squibb reported positive Phase 3 SCOUT-HCM data for Camzyos in adolescents with hypertrophic cardiomyopathy. FDA approved Sotyktu (deucravacitinib) for psoriatic arthritis on March 7 as first TYK2 inhibitor. Q1 2026 earnings April 30. Stock near 52-week high at $58.97. Oxford BioTherapeutics multi-year collaboration announced. Stock up 10.3% YTD.
Apr 10Bristol Myers Squibb raising dividend; Q1 2026 earnings April 30 amid tariff concerns.Mixed▶
Bristol Myers Squibb will report Q1 2026 results on April 30. Increased quarterly dividend to $0.63 (17th consecutive annual increase). Analysts expect EPS of $1.46 (-18.9% YoY). US tariff threats on branded drugs create regulatory risk. Mixed analyst sentiment with average $62.85 price target.
Apr 9Bristol Myers Squibb Gains on Positive Pulmonary Fibrosis Trial; Multiple Analyst Price Target IncreasesPositive▶
Bristol Myers Squibb closed up 2.65%, outperforming S&P 500. Stock delivered 32% return past six months. Guggenheim maintains Buy with $72 PT. Cantor Fitzgerald raised PT to $54. Jefferies raised PT to $70 (Buy). Positive Phase 3 SCOUT-HCM trial results for Camzyos. Long-term extension study launched for Admilparant in pulmonary fibrosis.
Apr 8FDA accepts Bristol-Myers iberdomide NDA with priority review; tariff concerns weigh.Mixed▶
FDA acceptance of iberdomide NDA with breakthrough designation, target action date Aug 17, 2026. Recent tariff headlines (up to 100% on branded drugs) create near-term regulatory risk. Q4 2025 EPS beat: $1.26 vs $1.14. Camzyos adolescent trial showed promising results. Guggenheim PT $72; Wells Fargo PT $60.
Apr 7Bristol Myers reports positive Camzyos adolescent trial; Q1 2026 earnings April 30.Positive▶
Bristol Myers Squibb announced positive Phase 3 SCOUT-HCM trial of Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy, showcased at American College of Cardiology 2026 and published in NEJM. Oral mezigdomide showed significant improvement in progression-free survival for relapsed/refractory multiple myeloma. Board declared quarterly dividend of $0.63 per share (+1.6% YoY), marking 17th consecutive annual increase. Q1 2026 earnings announced for April 30, 2026. TD Cowen conference participation scheduled.
Apr 6BMS Phase 3 SCOUT-HCM trial of Camzyos in adolescents meets primary endpoint.Positive▶
Bristol Myers Squibb reported positive Phase 3 SCOUT-HCM trial results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. Quarterly dividend $0.63 ($2.52 annualized, 4.2% yield). EVP David Elkins sold 30,000 shares April 1. FY2026 EPS guidance $6.05-6.35.
Apr 3Bristol Myers Squibb shares fell 3.8% on pharmaceutical tariff concerns, though positive Phase 3 SCOUT-HCM trial results for Camzyos reported.Mixed▶
Bristol Myers Squibb faced headwinds with a 3.8% stock decline following concerns about branded pharmaceutical tariffs. However, the company announced positive Phase 3 data for Camzyos (mavacamten) for obstructive hypertrophic cardiomyopathy in adolescents. The company also expanded its multiple myeloma program and deepened ALS research collaborations. Despite tariff concerns, the stock has surged 36% over the past six months. Analysts maintain Buy rating with $61.81 price target.
Apr 1Bristol Myers Squibb announces positive Camzyos adolescent trial results and schedules Q1 earnings for April 30.Positive▶
Bristol Myers Squibb will announce Q1 2026 results on April 30, 2026. Declared a quarterly dividend of $0.63 per share payable May 1, 2026. Positive Phase 3 SCOUT-HCM results for Camzyos in adolescents showing LS mean Valsalva LVOT gradient reduction of -48.0 mm Hg at Week 28, meeting primary endpoint. FDA and EU approvals expanding Opdivo indications for classical Hodgkin lymphoma announced March 20, 2026.
Mar 31Bristol Myers positive Phase 3 SCOUT-HCM results for Camzyos; expanded Opdivo approvals.Positive▶
Bristol Myers positive Phase 3 SCOUT-HCM for Camzyos (mavacamten) in adolescents March 29. Stock jumped 2.6% on expanded Opdivo approvals. Quarterly dividend $0.63. Growth Portfolio revenues $22.6B up 17%. Stock $59.70, P/E 16.92, 4.3% yield. Consensus $63 target.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $964.50 | +3.20% | +0.8% | 22.2x | 0.50 | $834.9B |
| JNJJOHNSON | $227.78 | -0.90% | -4.6% | 18.1x | 0.33 | $553.3B |
| MRKMERCK | $112.32 | +2.88% | -9.7% | 11.2x | 0.28 | $269.7B |
| PFEPFIZER | $26.37 | -1.25% | -4.1% | 9.5x | 0.39 | $151.9B |
| BMYBRISTOL | $58.19 | -3.97% | +2.1% | 9.9x | 0.27 | $123.7B |
| ZTSZOETIS | $114.35 | -0.54% | -2.8% | 15.2x | 0.97 | $48.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price between 50d and 200d. Testing 50d support.